Floatz Rating
D30/100
Confidence
Indicative
Sponsor
Masonic Cancer Center, University of Minnesota
Modality
mixture
Development Phase
N/A
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
15Indicative
Detailed axis rationale is planned and will be published soon.
No trial-level evidence is linked to this axis yet.
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Fanconi Anemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| 92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER (this asset) | Masonic Cancer Center, University of Minnesota | N/A | D · 30 |
| Cyclophosphamide | Porteus, Matthew, MD | P2/3 | BBB |
| Fludarabine | Porteus, Matthew, MD | P2/3 | BBB |
| Busulfanum | Masonic Cancer Center, University of Minnesota | P2/3 | BBB |
| Cyclosporin A | Fred Hutchinson Cancer Center | P2 | BBB |
| Nivestim | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2 | BBB |
| Prednisone | Fred Hutchinson Cancer Center | P2 | BB |
| Plerixafor | Assistance Publique - Hôpitaux de Paris | P2 | BB |
| Alemtuzumab | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | P2/3 | BB |
+34 more in the Fanconi Anemia cohort
Other indications for 92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Major Depressive Disorder | — | P1 | CCC · 48 |
| Obesity Disorder | — | P2 | CCC · 48 |
| Bipolar Disorder | — | N/A | D · 30 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. 92.3% TO NMT 93.8% ETHANOL BY WEIGHT IN WATER in Fanconi Anemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/923-to-nmt-938-ethanol-by-weight-in-water-fanconi-anemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →